Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.

Lagacé-Wiens PRS, Adam HJ, Poutanen S, Baxter MR, Denisuik AJ, Golden AR, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Golding G, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv22-iv31. doi: 10.1093/jac/dkz284.

PMID:
31505648
2.

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.

Denisuik AJ, Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv64-iv71. doi: 10.1093/jac/dkz289.

PMID:
31505647
3.

Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16.

Golden AR, Baxter MR, Davidson RJ, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG, Adam HJ; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv39-iv47. doi: 10.1093/jac/dkz286.

PMID:
31505644
4.

Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study.

McCracken MG, Adam HJ, Blondeau JM, Walkty AJ, Karlowsky JA, Hoban DJ, Zhanel GG, Mulvey MR; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv32-iv38. doi: 10.1093/jac/dkz285.

PMID:
31505643
5.

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Golden AR, Hink R, Lagacé-Wiens PRS, Walkty A, Mulvey MR, Schweizer F, Bay D, Hoban DJ, Karlowsky JA; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv5-iv21. doi: 10.1093/jac/dkz283.

PMID:
31505641
6.

The relationship between regional pain with or without neuropathic symptoms and chronic widespread pain.

McBeth J, Mulvey MR, Rashid A, Anderson J, Druce K.

Pain. 2019 Aug;160(8):1817-1823. doi: 10.1097/j.pain.0000000000001568.

7.

The relationship between regional pain with or without neuropathic symptoms and chronic widespread pain.

McBeth J, Mulvey MR, Rashid A, Anderson J, Druce K.

Pain. 2019 Apr 8. doi: 10.1097/j.pain.0000000000001568. [Epub ahead of print]

8.

[Interventions to support self-management in cancer pain].

ElMokhallalati Y, Mulvey MR, Bennett MI.

Schmerz. 2019 Jun;33(3):255-260. doi: 10.1007/s00482-019-0372-4. Review. German. No abstract available.

PMID:
31053936
9.

Genomic Investigation of the Emergence of Invasive Multidrug-Resistant Salmonella enterica Serovar Dublin in Humans and Animals in Canada.

Mangat CS, Bekal S, Avery BP, Côté G, Daignault D, Doualla-Bell F, Finley R, Lefebvre B, Bharat A, Parmley EJ, Reid-Smith RJ, Longtin J, Irwin RJ, Mulvey MR; Canadian Integrated Program for Antimicrobial Resistance Surveillance Public Health Partnership.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00108-19. doi: 10.1128/AAC.00108-19. Print 2019 Jun.

PMID:
31036694
10.

Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012-2016.

Martin I, Sawatzky P, Allen V, Lefebvre B, Hoang L, Naidu P, Minion J, Van Caeseele P, Haldane D, Gad RR, Zahariadis G, Corriveau A, German G, Tomas K, Mulvey MR.

Can Commun Dis Rep. 2019 Feb 7;45(2-3):45-53. doi: 10.14745/ccdr.v45i23a01. eCollection 2019 Feb 7.

11.

Two Hypervirulent Klebsiella pneumoniae Isolates Producing a bla KPC-2 Carbapenemase from a Canadian Patient.

Mataseje LF, Boyd DA, Mulvey MR, Longtin Y.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00517-19. doi: 10.1128/AAC.00517-19. Print 2019 Jul.

PMID:
30988151
12.

Cancer-Related Neuropathic Pain.

Edwards HL, Mulvey MR, Bennett MI.

Cancers (Basel). 2019 Mar 16;11(3). pii: E373. doi: 10.3390/cancers11030373. Review.

13.

Identification of a novel metallo-β-lactamase, CAM-1, in clinical Pseudomonas aeruginosa isolates from Canada.

Boyd DA, Lisboa LF, Rennie R, Zhanel GG, Dingle TC, Mulvey MR.

J Antimicrob Chemother. 2019 Jun 1;74(6):1563-1567. doi: 10.1093/jac/dkz066.

PMID:
30789204
14.

Molecular Basis for the Potent Inhibition of the Emerging Carbapenemase VCC-1 by Avibactam.

Mangat CS, Vadlamani G, Holicek V, Chu M, Larmour VLC, Vocadlo DJ, Mulvey MR, Mark BL.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02112-18. doi: 10.1128/AAC.02112-18. Print 2019 Apr.

15.

Interventions to support self-management in cancer pain.

ElMokhallalati Y, Mulvey MR, Bennett MI.

Pain Rep. 2018 Oct 5;3(6):e690. doi: 10.1097/PR9.0000000000000690. eCollection 2018 Nov. No abstract available.

16.

Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017).

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Boyd D, Bharat A, Mulvey MR, Charles M, Bergevin M, Zhanel GG.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):199-201. doi: 10.1016/j.diagmicrobio.2018.12.005. Epub 2018 Dec 14.

PMID:
30638654
17.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M, Nichol KA, Lagacé-Wiens P, Walkty AJ, Karlowsky JA, Hoban DJ, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2019 Mar 1;74(3):645-653. doi: 10.1093/jac/dky477.

PMID:
30500898
18.
19.

Characterization of a colistin-resistant Salmonella enterica 4,[5],12:i:- harbouring mcr-3.2 on a variant IncHI-2 plasmid identified in Canada.

Mulvey MR, Bharat A, Boyd DA, Irwin RJ, Wylie J.

J Med Microbiol. 2018 Dec;67(12):1673-1675. doi: 10.1099/jmm.0.000854. Epub 2018 Oct 23.

PMID:
30351266
20.

Results from the Canadian Nosocomial Infection Surveillance Program for detection of carbapenemase-producing Acinetobacter spp. in Canadian hospitals, 2010-16.

Boyd DA, Mataseje LF, Pelude L, Mitchell R, Bryce E, Roscoe D, Embree J, Katz K, Kibsey P, Lavallee C, Simor AE, Taylor G, Turgeon N, Langley JM, Amaratunga K, Mulvey MR; Canadian Nosocomial Infection Surveillance Program .

J Antimicrob Chemother. 2019 Feb 1;74(2):315-320. doi: 10.1093/jac/dky416.

PMID:
30312401
21.

A repeated cross-sectional study of the epidemiology of Campylobacter and antimicrobial resistant Enterobacteriaceae in free-living Canada geese in Guelph, Ontario, Canada.

Vogt NA, Pearl DL, Taboada EN, Reid-Smith RJ, Mulvey MR, Janecko N, Mutschall SK, Jardine CM.

Zoonoses Public Health. 2019 Feb;66(1):60-72. doi: 10.1111/zph.12529. Epub 2018 Oct 4.

PMID:
30288954
22.

Evaluation of Oxford Nanopore's MinION Sequencing Device for Microbial Whole Genome Sequencing Applications.

Tyler AD, Mataseje L, Urfano CJ, Schmidt L, Antonation KS, Mulvey MR, Corbett CR.

Sci Rep. 2018 Jul 19;8(1):10931. doi: 10.1038/s41598-018-29334-5.

23.

Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15.

Golden AR, Adam HJ, Karlowsky JA, Baxter M, Nichol KA, Martin I, Demczuk W, Van Caeseele P, Gubbay JB, Lefebvre B, Levett PN, Zahariadis G, Haldane D, Gad R, German G, Gilmour MW, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii20-vii31. doi: 10.1093/jac/dky157.

PMID:
29982573
24.

Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15.

Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii12-vii19. doi: 10.1093/jac/dky158.

PMID:
29982572
25.

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15.

Karlowsky JA, Adam HJ, Golden AR, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii5-vii11. doi: 10.1093/jac/dky156.

PMID:
29982570
26.

The evolving epidemiology of Clostridium difficile infection in Canadian hospitals during a postepidemic period (2009-2015).

Katz KC, Golding GR, Choi KB, Pelude L, Amaratunga KR, Taljaard M, Alexandre S, Collet JC, Davis I, Du T, Evans GA, Frenette C, Gravel D, Hota S, Kibsey P, Langley JM, Lee BE, Lemieux C, Longtin Y, Mertz D, Mieusement LMD, Minion J, Moore DL, Mulvey MR, Richardson S, Science M, Simor AE, Stagg P, Suh KN, Taylor G, Wong A, Thampi N; Canadian Nosocomial Infection Surveillance Program.

CMAJ. 2018 Jun 25;190(25):E758-E765. doi: 10.1503/cmaj.180013.

27.

Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016.

Demczuk WHB, Martin I, Desai S, Griffith A, Caron-Poulin L, Lefebvre B, McGeer A, Tyrrell GJ, Zhanel GG, Gubbay J, Hoang L, Levett PN, Van Caeseele P, Raafat Gad R, Haldane D, Zahariadis G, German G, Daley Bernier J, Strudwick L, Mulvey MR.

Vaccine. 2018 Jul 25;36(31):4701-4707. doi: 10.1016/j.vaccine.2018.06.018. Epub 2018 Jun 21.

PMID:
29937245
28.

Duration and determinants of hospice-based specialist palliative care: A national retrospective cohort study.

Allsop MJ, Ziegler LE, Mulvey MR, Russell S, Taylor R, Bennett MI.

Palliat Med. 2018 Sep;32(8):1322-1333. doi: 10.1177/0269216318781417. Epub 2018 Jun 6.

29.

Canada-Wide Epidemic of emm74 Group A Streptococcus Invasive Disease.

Teatero S, McGeer A, Tyrrell GJ, Hoang L, Smadi H, Domingo MC, Levett PN, Finkelstein M, Dewar K, Plevneshi A, Athey TBT, Gubbay JB, Mulvey MR, Martin I, Demczuk W, Fittipaldi N.

Open Forum Infect Dis. 2018 Apr 20;5(5):ofy085. doi: 10.1093/ofid/ofy085. eCollection 2018 May.

30.

Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa.

German GJ, Gilmour M, Tipples G, Adam HJ, Almohri H, Bullard J, Dingle T, Farrell D, Girouard G, Haldane D, Hoang L, Levett PN, Melano R, Minion J, Needle R, Patel SN, Rennie R, Reyes RC, Longtin J, Mulvey MR.

Can Commun Dis Rep. 2018 Jan 4;44(1):29-34. eCollection 2018 Jan 4.

31.

Utilization of Nucleic Acid Amplification Testing Samples for Antimicrobial Resistance Surveillance in Remote Canadian Communities.

Mulvey MR, Martin I, Wong T.

Sex Transm Dis. 2018 Aug;45(8):e61. doi: 10.1097/OLQ.0000000000000860. No abstract available.

PMID:
29664766
32.

Cooperative Recognition of Internationally Disseminated Ceftriaxone-Resistant Neisseria gonorrhoeae Strain.

Lahra MM, Martin I, Demczuk W, Jennison AV, Lee KI, Nakayama SI, Lefebvre B, Longtin J, Ward A, Mulvey MR, Wi T, Ohnishi M, Whiley D.

Emerg Infect Dis. 2018 Apr;24(4). doi: 10.3201/eid2404.171873.

33.

A critical appraisal of gabapentinoids for pain in cancer patients.

Jordan RI, Mulvey MR, Bennett MI.

Curr Opin Support Palliat Care. 2018 Jun;12(2):108-117. doi: 10.1097/SPC.0000000000000337. Review.

34.

Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics.

MacNair CR, Stokes JM, Carfrae LA, Fiebig-Comyn AA, Coombes BK, Mulvey MR, Brown ED.

Nat Commun. 2018 Jan 31;9(1):458. doi: 10.1038/s41467-018-02875-z.

35.

A Comparison of Real-Time Polymerase Chain Reaction Assays for the Detection of Antimicrobial Resistance Markers and Sequence Typing From Clinical Nucleic Acid Amplification Test Samples and Matched Neisseria gonorrhoeae Culture.

Peterson SW, Martin I, Demczuk W, Hoang L, Wylie J, Lefebvre B, Labbé AC, Naidu P, Haldane D, Mulvey MR.

Sex Transm Dis. 2018 Feb;45(2):92-95. doi: 10.1097/OLQ.0000000000000707.

PMID:
29329177
36.

Characterization of OXA-48-like carbapenemase producers in Canada, 2011-14.

Mataseje LF, Boyd DA, Fuller J, Haldane D, Hoang L, Lefebvre B, Melano RG, Poutanen S, Van Caeseele P, Mulvey MR.

J Antimicrob Chemother. 2018 Mar 1;73(3):626-633. doi: 10.1093/jac/dkx462.

PMID:
29272439
37.

Self-management toolkit and delivery strategy for end-of-life pain: the mixed-methods feasibility study.

Bennett MI, Mulvey MR, Campling N, Latter S, Richardson A, Bekker H, Blenkinsopp A, Carder P, Closs J, Farrin A, Flemming K, Gallagher J, Meads D, Morley S, O'Dwyer J, Wright-Hughes A, Hartley S.

Health Technol Assess. 2017 Dec;21(76):1-292. doi: 10.3310/hta21760.

38.

Risk factors for acquisition of multidrug-resistant Escherichia coli and development of community-acquired urinary tract infections.

Ukah UV, Glass M, Avery B, Daignault D, Mulvey MR, Reid-Smith RJ, Parmley EJ, Portt A, Boerlin P, Manges AR.

Epidemiol Infect. 2018 Jan;146(1):46-57. doi: 10.1017/S0950268817002680. Epub 2017 Dec 12.

PMID:
29229015
39.

Neuropathic pain in cancer: systematic review, performance of screening tools and analysis of symptom profiles.

Mulvey MR, Boland EG, Bouhassira D, Freynhagen R, Hardy J, Hjermstad MJ, Mercadante S, Pérez C, Bennett MI.

Br J Anaesth. 2017 Oct 1;119(4):765-774. doi: 10.1093/bja/aex175.

40.

Evaluation of a Modified Carbapenem Inactivation Method for Detection of Carbapenemases in Pseudomonas aeruginosa.

Lisboa LF, Turnbull L, Boyd DA, Mulvey MR, Dingle TC.

J Clin Microbiol. 2017 Dec 26;56(1). pii: e01234-17. doi: 10.1128/JCM.01234-17. Print 2018 Jan. No abstract available.

41.

Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis.

Kane CM, Mulvey MR, Wright S, Craigs C, Wright JM, Bennett MI.

Palliat Med. 2018 Jan;32(1):276-286. doi: 10.1177/0269216317711826. Epub 2017 Jun 12.

42.

Phylogenetic analysis of emergent Streptococcus pneumoniae serotype 22F causing invasive pneumococcal disease using whole genome sequencing.

Demczuk WHB, Martin I, Hoang L, Van Caeseele P, Lefebvre B, Horsman G, Haldane D, Gubbay J, Ratnam S, German G, Daley Bernier J, Strudwick L, McGeer A, Zhanel GG, Van Domselaar G, Graham M, Mulvey MR.

PLoS One. 2017 May 22;12(5):e0178040. doi: 10.1371/journal.pone.0178040. eCollection 2017.

43.

Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.

Lagacé-Wiens PRS, Adam HJ, Laing NM, Baxter MR, Martin I, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2017 Aug 1;72(8):2273-2277. doi: 10.1093/jac/dkx147.

PMID:
28505331
44.

Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.

Walkty A, Lagace-Wiens P, Adam H, Baxter M, Karlowsky J, Mulvey MR, McCracken M, Zhanel GG.

Diagn Microbiol Infect Dis. 2017 Jan;87(1):60-63. doi: 10.1016/j.diagmicrobio.2016.10.003. Epub 2016 Oct 7.

PMID:
28336136
45.

WGS to predict antibiotic MICs for Neisseria gonorrhoeae.

Eyre DW, De Silva D, Cole K, Peters J, Cole MJ, Grad YH, Demczuk W, Martin I, Mulvey MR, Crook DW, Walker AS, Peto TEA, Paul J.

J Antimicrob Chemother. 2017 Jul 1;72(7):1937-1947. doi: 10.1093/jac/dkx067.

46.

A Novel Hybrid Plasmid Carrying Multiple Antimicrobial Resistance and Virulence Genes in Salmonella enterica Serovar Dublin.

Mangat CS, Bekal S, Irwin RJ, Mulvey MR.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02601-16. doi: 10.1128/AAC.02601-16. Print 2017 Jun.

47.

Neisseria gonorrhoeae Sequence Typing for Antimicrobial Resistance, a Novel Antimicrobial Resistance Multilocus Typing Scheme for Tracking Global Dissemination of N. gonorrhoeae Strains.

Demczuk W, Sidhu S, Unemo M, Whiley DM, Allen VG, Dillon JR, Cole M, Seah C, Trembizki E, Trees DL, Kersh EN, Abrams AJ, de Vries HJC, van Dam AP, Medina I, Bharat A, Mulvey MR, Van Domselaar G, Martin I.

J Clin Microbiol. 2017 May;55(5):1454-1468. doi: 10.1128/JCM.00100-17. Epub 2017 Feb 22.

48.

Enterobacter cloacae Complex Isolates Harboring blaNMC-A or blaIMI-Type Class A Carbapenemase Genes on Novel Chromosomal Integrative Elements and Plasmids.

Boyd DA, Mataseje LF, Davidson R, Delport JA, Fuller J, Hoang L, Lefebvre B, Levett PN, Roscoe DL, Willey BM, Mulvey MR.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02578-16. doi: 10.1128/AAC.02578-16. Print 2017 May.

49.

A Whole-Genome Sequencing Approach To Study Cefoxitin-Resistant Salmonella enterica Serovar Heidelberg Isolates from Various Sources.

Edirmanasinghe R, Finley R, Parmley EJ, Avery BP, Carson C, Bekal S, Golding G, Mulvey MR.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01919-16. doi: 10.1128/AAC.01919-16. Print 2017 Apr.

50.

Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015).

Walkty A, Karlowsky JA, Adam HJ, Lagacé-Wiens P, Baxter M, Mulvey MR, McCracken M, Poutanen SM, Roscoe D, Zhanel GG.

CMAJ Open. 2016 Oct 26;4(4):E641-E645. doi: 10.9778/cmajo.20160080. eCollection 2016 Oct-Dec.

Supplemental Content

Loading ...
Support Center